Ashraf F Nabhan1, Noha H Rabie. 1. Department of Obstetrics and Gynecology, University of Ain Shams, Cairo, Egypt. ashraf.nabhan@gmail.com
Abstract
OBJECTIVE: To compare the effectiveness, safety, and affordability of isosorbide mononitrate with alendronate for postmenopausal osteoporosis. METHODS: A randomized controlled trial of 60 postmenopausal women with osteoporosis. Participants were randomly assigned to receive either 20 mg daily of isosorbide mononitrate or 70 mg weekly of alendronate for 12 months. Bone mineral density (BMD) was measured using dual X-ray absorptiometry (DXA) at baseline and after 12 months. RESULTS: Both groups showed significant improvement in BMD. Isosorbide mononitrate yielded a comparable effect to alendronate for BMD and T-score at the end of the follow-up period. For BMD and T score the mean differences between the 2 groups were -0.005 (95% CI, -0.02 to 0.03) and 0.31 (95% CI, -0.03 to 0.64), respectively. A 10.8% and 12.1% change in BMD after 12 months was seen for isosorbide mononitrate and alendronate, respectively. CONCLUSION:Isosorbide mononitrate is comparable to alendronate. Nitric oxide donors may be an effective and affordable therapy to improve bone mineral density.
RCT Entities:
OBJECTIVE: To compare the effectiveness, safety, and affordability of isosorbide mononitrate with alendronate for postmenopausal osteoporosis. METHODS: A randomized controlled trial of 60 postmenopausal women with osteoporosis. Participants were randomly assigned to receive either 20 mg daily of isosorbide mononitrate or 70 mg weekly of alendronate for 12 months. Bone mineral density (BMD) was measured using dual X-ray absorptiometry (DXA) at baseline and after 12 months. RESULTS: Both groups showed significant improvement in BMD. Isosorbide mononitrate yielded a comparable effect to alendronate for BMD and T-score at the end of the follow-up period. For BMD and T score the mean differences between the 2 groups were -0.005 (95% CI, -0.02 to 0.03) and 0.31 (95% CI, -0.03 to 0.64), respectively. A 10.8% and 12.1% change in BMD after 12 months was seen for isosorbide mononitrate and alendronate, respectively. CONCLUSION:Isosorbide mononitrate is comparable to alendronate. Nitric oxide donors may be an effective and affordable therapy to improve bone mineral density.
Authors: Hema Kalyanaraman; Ghania Ramdani; Jisha Joshua; Nadine Schall; Gerry R Boss; Esther Cory; Robert L Sah; Darren E Casteel; Renate B Pilz Journal: J Bone Miner Res Date: 2016-09-07 Impact factor: 6.741
Authors: Ghania Ramdani; Nadine Schall; Hema Kalyanaraman; Nisreen Wahwah; Sahar Moheize; Jenna J Lee; Robert L Sah; Alexander Pfeifer; Darren E Casteel; Renate B Pilz Journal: J Endocrinol Date: 2018-06-18 Impact factor: 4.286
Authors: Sander Pouwels; Arief Lalmohamed; Tjeerd van Staa; Cyrus Cooper; Patrick Souverein; Hubertus G Leufkens; Lars Rejnmark; Anthonius de Boer; Peter Vestergaard; Frank de Vries Journal: J Clin Endocrinol Metab Date: 2010-02-03 Impact factor: 5.958
Authors: Melissa N Conley; Cooper Roberts; Thomas J Sharpton; Urszula T Iwaniec; Norman G Hord Journal: Mol Nutr Food Res Date: 2017-03-30 Impact factor: 5.914